Rhematoid ArthritisPhase 4ORAL STRATEGYNCT02187055
An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
A Phase 4 study testing Tofacitinib with methotrexate, Tofacitinib without methotrexate and Adalimumab with methotrexate in people with Rhematoid Arthritis, run by Pfizer at 215 sites in 25 countries.
Trial summary
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Rhematoid Arthritis
- What is being tested?
- Tofacitinib with methotrexate, Tofacitinib without methotrexate and Adalimumab with methotrexate
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,152 participants
- Where
- 215 sitesin 25 countries
- Study dates
- Aug 2014to Dec 2016
- Phase
- Phase 4
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Have moderate to severe rheumatoid arthritis
- On methotrexate but inadequately controlled
- Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection
- Subjects must use contraception
Who cannot join
- Subjects who have been previously treated with adalimumab or Tofacitinib
- Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- Subjects with specific laboratory test abnormalities
- Subjects with specific types of infections
Trial locations and contacts
215 sites in 25 countries.
215 sites in 25 countries
United States60 sites
AARDS Research, Inc.
Aventura, Florida, 33180
Arthritis and Rheumatic Disease Specialties
Aventura, Florida, 33180
Ochsner Clinic Baton Rouge
Baton Rouge, Louisiana, 70809
Accurate Clinical Management, LLC
Baytown, Texas, 77521
Joao M. A. Nascimento
Bridgeport, Connecticut, 06606
Low Country Rheumatology, PA
Charleston, South Carolina, 29406
Coeur D'Alene Arthritis Clinic
Coeur d'Alene, Idaho, 83814
Medvin Clinical Research
Covina, California, 91722
Arthritis Care And Diagnostic Center, P.A.
Dallas, Texas, 75231
Metroplex Clinical Research Center
Dallas, Texas, 75231
Altoona Center For Clinical Research
Duncansville, Pennsylvania, 16635
Riverside Clinical Research
Edgewater, Florida, 32132
Arthritis and Osteoporosis Treatment and Research Center
Flowood, Mississippi, 39232
Centre for Rheumatology, Immunology and Arthritis
Fort Lauderdale, Florida, 33309
Arthritis Treatment Center
Frederick, Maryland, 21702
St. Jude Hospital Yorba Linda DBA St. Joseph Heritage Healthcare
Fullerton, California, 92835
Arthrocare, Arthritis Care & Research, PC
Gilbert, Arizona, 85234
Accurate Clinical Management, LLC
Houston, Texas, 77004
Rheumatology Clinic of Houston, PA
Houston, Texas, 77065
Houston Institute For Clinical Research
Houston, Texas, 77074
HealthCare Partners Medical Group
Huntington Beach, California, 92646
Rheumatology Associates of North Alabama, PC
Huntsville, Alabama, 35801
Institute of Arthritis Research
Idaho Falls, Idaho, 83404
Diagnostic Rheumatology and Research PC
Indianapolis, Indiana, 46227
West Tennessee Research Institute
Jackson, Tennessee, 38305
Jacksonville Center for Clinical Research
Jacksonville, Florida, 32216
Jasper Clinic
Kalamazoo, Michigan, 49007
Keck Medicine of USC - Division of Rheumatology
Los Angeles, California, 90033
University of Southern California (USC) Norris Comprehensive Cancer Center
Los Angeles, California, 90033
Ronald Reagan UCLA Medical Center - Drug Information Center
Los Angeles, California, 90095
UCLA David Geffen School of Medicine, Division of Rheumatology
Los Angeles, California, 90095
Arthritis & Osteoporosis Associates, LLP
Lubbock, Texas, 79424
Southwest Rheumatology Research, LLC.
Mesquite, Texas, 75150
Trinity Health Center - Medical Arts
Minot, North Dakota, 58701
Arthritis and Diabetes Clinic, Inc
Monroe, Louisiana, 71203
Lynn Health Science Institute
Oklahoma City, Oklahoma, 73112
Omega Research Consultants, LLC
Orlando, Florida, 32804
Arthritis Center, Inc.
Palm Harbor, Florida, 34684
Gulf Region Clinical Research Institute Llc
Pensacola, Florida, 32514
Arthritis Group
Philadelphia, Pennsylvania, 19152-3303
Medvin Clinical Research
Placentia, California, 92870
Dr. Prem C. Chatpar M.D.,LLC
Plainview, New York, 11803
PMG Research of Salisbury, LLC
Salisbury, North Carolina, 28144
Rowan Diagnostic Clinic
Salisbury, North Carolina, 28144
Accurate Clinical Research, Inc.
San Antonio, Texas, 78229
Arthritis & Osteoporosis Center of South Texas
San Antonio, Texas, 78232
San Diego Arthritis Medical Clinic
San Diego, California, 92108
Arthritis Northwest, PLLC
Spokane, Washington, 99204
Clinvest/ A Division of Banyan Group, Inc.
Springfield, Missouri, 65807
St. Louis Center For Clinical Research Barbara Caciolo, MD
St Louis, Missouri, 63128
West Broward Rheumatology Associates, Inc.
Tamarac, Florida, 33321
BayCare Medical Group Inc
Tampa, Florida, 33614
Inland Rheumatology Clinical Trials, Inc.
Upland, California, 91786
Medvin Clinical Research
Van Nuys, California, 91405
Deerbrook Medical Associates
Vernon Hills, Illinois, 60061
The Center for Arthritis and Rheumatism
Vero Beach, Florida, 32960
The Office of Alastair C. Kennedy, MD
Vero Beach, Florida, 32960
Medvin Clinical Research
Whittier, California, 90602
PMG Research of Wilmington
Wilmington, North Carolina, 28401
Advanced Clinical Research of Orlando, Inc.
Winter Garden, Florida, 34787
Poland14 sites
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w Bydgoszczy,
Bydgoszcz, 85-168
Centrum Medyczne SILESIANA Sp. z o.o.
Bytom, 41-902
Nzoz Bif-Med
Bytom, 41-902
Centrum Kliniczno-Badawcze J.Brzezicki, B.Gornikiewicz-Brzezicka
Elblag, 82-300
Synexus Polska Sp. z o.o. Oddzial w Gdyni
Gdynia, 81-384
Synexus Polska Sp. z o.o. Oddzial w Katowicach
Katowice, 40-040
Medica Pro Familia Sp. z o.o. S.K.A. Oddzial Krakow
Krakow, Malopolska, 30-002
Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz, 90-242
Lecznica MAK-MED, NZOZ
Nadarzyn, 05-830
Prywatna Praktyka Lekarska
Poznan, 61-397
Centrum Medyczne Amed
Warsaw, WOJ Mazowieckie, 01-518
Synexus Polska Sp. z o.o. Oddzial w Warszawie
Warsaw, 01192
MTZ Clinical Research Sp. z o.o.
Warsaw, 02-106
Synexus Polska Sp. z o.o. Oddzial we Wroclawiu
Wroclaw, 50-088
Russia14 sites
SAHI of KR "Kemerovo Regional Clinical Hospital"
Kemerovo, 650066
SBEI HPE First Moscow State Medical University n.a.I.M.Sechenov of MoH of RF based on UCH#1
Moscow, 119991
CJSC "European Medical Center"
Moscow, 129090
SBEI HPE Novosibirsk State Medical University of MoH of RF
Novosibirsk, 630102
State Budgetary Healthcare Institution "Orenburg Regional Clinical Hospital"
Orenburg, 460018
Republic Hospital n.a. V.A. Baranov
Petrozavodsk, Karelia Republic, 185019
State Budgetary Healthcare Institution of Karelia Republic "Republic Hospital n.a. V.A. Baranov"
Petrozavodsk, Karelia Republic, 185019
State Budgetary Institution of Ryazan Region "Regional Clinical Cardiology Dispensary"
Ryazan, 390026
Limited Liability Company AVA-PETER
Saint Petersburg, 191014
State Budgetary Institution of Healthcare "Samara Regional Clinical Hospital n.a. V.D. Seredavin"
Samara, 443095
State Institution of Healthcare "Regional Clinical Hospital"
Saratov, 410053
Non-state Healthcare Institution "Regional Hospital at Smolensk Station of OJSC "Russian Railways"
Smolensk, 214025
State Autonomous Healthcare lnstitution of Yarostavl Region
Yaroslavl, 150003
State Budgetary Healthcare Institution of Yaroslavl Region "Clinical Hospital #3"
Yaroslavl, 150007
Mexico13 sites
Investigacion y Biomedica de Chihuahua, SC
Chihuahua City, 31000
Centro de Investigacion de Tratamientos Innovadores de Sinaloa S.C.
Culiacán, Sinaloa, 80000
Centro de Investigacion en Tratamientos Innovadores de Sinaloa S.C.
Culiacán, Sinaloa, 80000
Centro Integral en Reumatologia, SA de CV
Guadalajara, Jalisco, 44160
Centro de Integral en Reumatologia SA de CV
Jalisco, 44160
Centro Multidisciplinario para el Desarrollo Especializado de la Invetigacion Clinica en Yucatan
Mérida, Yucatán, 97133
Departamento de Imagen de Hospital Star Medica Merida
Mérida, Yucatán, 97133
Laboratorio clínico del Hospital Star Medica Merida
Mérida, Yucatán, 97133
Storage for lab kits and study materials
Mérida, Yucatán, 97133
CINTRE, Centro de Investigacion y Tratamiento Reumatologico S.C. Consultorio Medico de Reumatologia
Mexico City, Mexico City, 11850
Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi, S.C.
San Luis Potosí City, 78213
Unidad de Investigaciones Reumatologicas A.C.
San Luis Potosí City, 78290
Unidad de Enfermedades Reumaticas y Cronico Degenerativas S. C.
Torreón, Coahuila, 27000
South Africa12 sites
Iatros International
Bloemfontein, Free State, 9301
Arthritis Clinical Research Trials
Cape Town, Western Cape, 7405
Panorama Medical Centre
Cape Town, Western Cape, 7500
Netcare St Augustine's Hospital
Durban, KwaZulu-Natal, 4001
LCS Clinical Research Unit
Johannesburg, Gauteng, 2021
WCR: Wits Clinical Research Charlotte Maxeke Johannesburg Academic Hospital
Johannesburg, Gauteng, 2193
WCR: Wits Clinical Research
Johannesburg, Gauteng, 2193
Charlotte Maxeke Johannesburg Academic Hospital
Parktown, Johannesburg, Gauteng, 2193
Clinical Research Unit, University of Pretoria
Pretoria, Gauteng, 0002
Netcare Jakaranda Hospital
Pretoria, Gauteng, 0002
University of Pretoria
Pretoria, Gauteng, 0002
Wineland Medical Research Centre
Stellenbosch, Western Cape, 7600
Romania11 sites
Spitalul Judetean de Urgenta "Dr. Constantin Opris"
Baia Mare, Maramureş, 430031
S.C. Clinica Somesan S.R.L.
Baia Mare, Maramureş, 430352
Ianuli Med Consult SRL, Reumatologie
Bucharest, 010976
Spitalul Clinic Sf. Maria, Medicina interna - Reumatologie
Bucharest, 011172
Spitalul Clinic Sf. Maria
Bucharest, 011172
Spitalul Clinic "Dr. I. Cantacuzino"
Bucharest, 020475
Centrul Clinic de Boli Reumatismale "Dr. Ion Stoia"
Bucharest, 020983
Spitalul Clinic Judetean de Urgenta Cluj Napoca Reumatologie
Cluj-Napoca, Cluj, 400006
Spitalul Clinic Judetean de Urgenta - "Sf.Apostol Andrei" Galati
Galati, 800578
Spitalul Clinic de Recuperare Iasi
Iași, 700661
Covamed Serv SRL
Sfantu Gheorghe, Covasna, 520052
Philippines10 sites
Perpetual Succour Hospital
Cebu City, 6000
Brokenshire Integrated Health Ministries, Inc.
Davao City, Davao DEL SUR, 8000
Davao Doctors Hospital
Davao City, 8000
Iloilo Doctors' Hospital, Inc
Iloilo City, Iloilo, 5000
St. Paul's Hospital of Iloilo, Inc.
Iloilo City, 5000
Mary Mediatrix Medical Center
Lipa City, Batangas, 4217
University of the Philippines Manila-Philippine General Hospital
Manila, National Capital Region, 1000
Jose R. Reyes Memorial Medical Center-Rayuma Klinik
Manila, National Capital Region, 1003
St. Luke's Medical Center
Quezon City, National Capital Region, 1102
Far Eastern University - NRMF Medical Center
Quezon City, National Capital Region, 1118
Bulgaria9 sites
UMHAT "Dr. Georgi Stranski" EAD
Pleven, 5800
MHAT "Kaspela" EOOD
Plovdiv, 4002
MHAT EUROHOSPITAL Plovdiv
Plovdiv, 4004
MHAT Akta Medika OOD
Rousse, 5400
MHAT Ruse AD
Rousse, 7002
MHAT Shumen AD
Shumen, 9700
NMTH Tsar Boris Clinic of Internal Diseases
Sofia, 1233
MHAT Lyulin EAD
Sofia, 1336
MHAT "Targovishte" AD
Targovisthe, 7700
Australia6 sites
Royal Prince Alfred Hospital
Camperdown, New South Wales, 2050
Emeritus Research
Malvern East, Victoria, 3145
Pacific Private Clinic
Southport, Queensland, 4215
QML Pathology
Southport, Queensland, 4215
RK Will Pty Ltd
Victoria Park, Western Australia, 6100
The Queen Elizabeth Hospital
Woodville South, South Australia, 5011
South Korea6 sites
Kyungpook National University Hospital
Daegu, 41944
Daegu Catholic University Medical Center
Daegu, 42472
Chonnam National University Hospital
Gwangju, 61469
Inha University Hospital
Jung-Gu, Incheon, 22332
Hanyang University Seoul Hospital
Seoul, 04763
Konkuk University Medical Center
Seoul, 05030
Spain6 sites
Complexo Hospitalario Universitario A Coruna
A Coruña, 15006
Hospital Clinic de Barcelona
Barcelona, 08036
Hospital Universitario Fundacion Jimenez Diaz
Madrid, 28040
Hospital Regional Universitario de Malaga
Málaga, 29009
Complejo Hospitalario Universitario de Santiago de Compostela, Hospital Clinico Universitario
Santiago de Compostela, A Coruna, 15706
Hospital Infanta Luisa
Seville, 41010
Taiwan6 sites
Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Hualien City, 97002
Kaohsiung Medical University Chung-Ho Memorial Hospital - New
Kaohsiung City, 807
Kaohsiung Veterans General Hospital
Kaohsiung City, 81362
Chung Shan Medical University Hospital
Taichung, Taiwan ROC, 402
Taipei Veterans General Hospital
Taipei, 11217
Chang Gung Medical Foundation - Linkou Branch
Taoyuan County, 33305
Argentina5 sites
Organizacion Medica de Investigacion S.A - OMI
Buenos Aires, 1015
Atencion Integral en Reumatologia (AIR)
CABA, Buenos Aires, C1426AAL
CER San Juan, Centro Polivalente de Asistencia e Investigacion Clinica
San Juan, 5400
Centro Medico Privado de Reumatologia
San Miguel de Tucumán, Tucumán Province, 4000
Centro Radiologico Luis Mendez Collado SRL
San Miguel de Tucumán, Tucumán Province, 4000
Czechia5 sites
Revmatologie s.r.o.
Brno, 63800
Revmacentrum MUDr. Mostera, s.r.o.
Brno-Židenice, Czech Republic, 615 00
Revmatologicka ambulance
Česká Lípa, 470 01
Vesalion, s.r.o.
Ostrava- Moravska Ostrava, 702 00
Revmatologie
Prague, 140 00
Thailand5 sites
Phramongkutklao Hospital
Bangkok, Rajthevi, 10400
Cardiology Unit,Department of Medicine, Faculty of Medicine, Ramathibodi Hospital,Mahidol University
Bangkok, 10400
Div. of Allergy Immunology and Rheumatology, Dept. of Medicine,
Bangkok, 10400
Siriraj Hospital Mahidol University
Bangkok, 10700
Songklanagarind Hospital - Prince of Songkhla University
Songkhla, 90110
United Kingdom5 sites
The Royal Wolverhamptons NHS Trust
Cannock, WS11 5XY
The Dudley Group NHS Foundation Trust
Dudley, WEST Midlands, DY1 2HQ
The Leeds Teaching Hospitals NHS Trust
Leeds, LS7 4SA
Aintree University Hospital NHS Foundation Trust
Liverpool, L9 7AL
Royal Free London NHS Foundation Trust
London, NW3 2QG
Chile4 sites
Quantum Research Ltda
Puerto Varas, Los Lagos Region, 5550170
Quantum Research
Puerto Varas, Los Lagos Region, 5550170
Prosalud
Santiago, Santiago Metropolitan, 7510047
Estudios Clinicos Quinta Region Ltda.
Viña del Mar, Valparaiso, 2520997
Israel4 sites
Bnai Zion Medical Center
Haifa, 31048
Rambam Health Care Campus
Haifa, 3109601
Hadassah Medical Center
Jerusalem, 91120
The Chaim Sheba Medical Center
Tel HaShomer, 5262000
Peru4 sites
Unidad de Investigacion en Medicina Interna y Enfermedades criticas-Hogar Clinica San Juan de Dios
Arequipa, 04020
ABK REUMAR S.R.L. de Medicentro Biociencias_ BIO CIENCIAS PERU S.R.L.
Lima, 21
Instituto Peruano del Hueso y la Articulacion
Lima, 27
Investigaciones Clinicas S.A.C.
Lima, 33
Turkey (Türkiye)4 sites
Ankara Universitesi Tip Fakultesi Ibn-i Sina Hastanesi
Ankara, 06100
Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uyg. ve Eg.
Samsun, 55139
Ondokuz Mayis Universitesi Tip Fakultesi Saglik Uygulama ve Egitim Merkezi
Samsun, 55139
Cumhuriyet Universitesi Tip Fakultesi Hastanesi
Sivas, 58140
Estonia3 sites
Foundation Parnu Hospital
Pärnu, 80010
East-Tallinn Central Hospital Ltd
Tallinn, 11312
North Estonia Medical Centre Foundation
Tallinn, 13419
Lithuania3 sites
Alytaus District S. Kudirkos Hospital
Alytus, LT-62114
VAKK "Clinic of Dr. Kilda"
Kaunas, LT-50128
PI Republican Siauliai Hospital
Šiauliai, LT-76231
Bosnia and Herzegovina2 sites
University Hospital Clinical Center Banja Luka
Banja Luka, Republika Srpska, 78000
University Clinical Center Tuzla
Tuzla, 75000
Canada2 sites
Kw Musculoskeletal Research Inc
Kitchener, Ontario, N2M 5N6
Centre de Recherche Musculo-Squelettique
Trois-Rivières, Quebec, G8Z 1Y2
About this study
Official title: A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.
- Conditions
- Rhematoid Arthritis
- Being tested
- Tofacitinib with methotrexate, Tofacitinib without methotrexate, Adalimumab with methotrexate
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Tofacitinib with methotrexateDrug
Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Tofacitinib without methotrexateDrug
Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Adalimumab with methotrexateBiological
Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
| Study group | Role | What they receive |
|---|---|---|
| Tofacitinib 5 mg twice daily with methotrexate | Experimental | Not described Receives: Drug: Tofacitinib with methotrexate |
| Tofacitinib 5 mg twice daily monotherapy | Experimental | Not described Receives: Drug: Tofacitinib without methotrexate |
| Adalimumab with methotrexate | Active comparator | Not described Receives: Biological: Adalimumab with methotrexate |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6
ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.
Measured: Month 6
Secondary outcomes (30)
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 centimeter (cm) visual analogue scale (VAS) (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI less than or equal to (≤) 3.3 indicates disease remission, >3.4 to 11 indicates low disease activity, >11 to 26 indicates moderate disease activity, and >26 indicates high disease activity.
Measured: Month 6
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, >2.8 to 10 indicates low disease activity, >10 to 22 indicates moderate disease activity, and >22 indicates high disease activity.
Measured: Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (millimeters [mm]) + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and less than (<) 2.6 indicates remission.
Measured: Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-3 (ESR) ≤3.2 indicates low disease activity, >3.2 to 5.1 indicates moderate to high disease activity, and <2.6 indicates remission.
Measured: Month 6
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6
To meet the ACR-EULAR Boolean remission criteria, a participant must satisfy all of the following: TJC ≤1 and SJC ≤1 (both based on a 28-joint assessment), CRP ≤1 mg/dL, and PtGA ≤1 on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity).
Measured: Month 6
Percentage of Participants Achieving SDAI ≤3.3 at Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission.
Measured: Month 6
Percentage of Participants Achieving CDAI ≤2.8 at Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission.
Measured: Month 6
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) <2.6 indicates disease remission.
Measured: Month 6
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA (mm) + 0.96. Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (CRP) <2.6 indicates remission.
Measured: Month 6
Percentage of Participants Achieving SDAI ≤11 at Month 6
SDAI is the numerical sum of five outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity), and CRP (mg/dL). SDAI total score ranges from 0 to 86. SDAI ≤3.3 indicates disease remission, >3.4 to 11 indicates low disease activity.
Measured: Month 6
Percentage of Participants Achieving CDAI ≤10 at Month 6
CDAI is the numerical sum of four outcome parameters: TJC and SJC both based on a 28-joint assessment, PtGA and PGA both assessed on a 0 to 10 cm VAS (higher scores indicate greater affection due to disease activity). CDAI total score ranges from 0 to 76. CDAI ≤2.8 indicates disease remission, >2.8 to 10 indicates low disease activity.
Measured: Month 6
Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6
DAS28-4 (ESR) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and ESR (mm/hour) using the following: DAS28-4(ESR) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.70*ln(ESR) + 0.014* PtGA (mm). Total score range: 0 to 9.4, higher score indicates higher disease activity. DAS28-4 (ESR) ≤3.2 indicates low disease activity.
Measured: Month 6
Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6
DAS28-4 (CRP) was calculated from the SJC and TJC (both based on a 28-joint assessment), PtGA (assessed on a 0 to 10 cm VAS; higher scores indicate greater affection due to disease activity) and CRP (mg/L) using the following: DAS28-4(CRP) = 0.56*sqrt(TJC28) + 0.28*sqrt(SJC28) + 0.36*ln(CRP+1) + 0.014* PtGA + 0.96. Total score range: 0 to 9.4, higher score indicated higher disease activity. DAS28-4 (CRP) ≤3.2 indicates low disease activity.
Measured: Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6
ACR20 response is a ≥20% improvement in TJC or SJC and 20% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Measured: Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6
ACR70 response is a ≥70% improvement in TJC or SJC and 70% improvement in 3 of the following 5 criteria: 1) PGA of disease activity, 2) PtGA of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) CRP at each visit.
Measured: Month 6
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty.
Measured: Month 6
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6
The HAQ-DI is a participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dressing and grooming, arising, eating, walking, reach, grip, hygiene and other activities over the past week. Each activity category consists of 2 to 3 items. Each item is scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Any activity requiring assistance from another individual or the use of an assistive device adjusts to a minimum score of 2 to represent a more limited functional status. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score ranges from 0 to 3 where 0 = least difficulty and 3 = extreme difficulty. A decrease of 0.22 or more is considered a positive response.
Measured: Month 6
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the physical component summary (PCS) score and the mental component summary (MCS) score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the United States (US) 1998 general population norms. The resulting norm-based scores for both the SF-36 version 2 (v2) and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher PCS score represents better physical health status.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6
The SF-36 health survey is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The health domains are aggregated into two summary scores known as the PCS score and the MCS score. Normalized domain scores, PCS and MCS scores are used in the analyses. The component and domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher MCS score represents better physical health status.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 10 items of the physical functioning scale represent levels and kinds of limitations between extremes of physical activities, including lifting and carrying groceries; climbing stairs; bending, kneeling, or stooping; walking moderate distances; self-care limitations. The physical functioning items capture the presence and extent of physical limitations using a 3-level response continuum. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher physical functioning domain score represents better physical functioning.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6
SF-36v2 acute is a 36-item measure evaluating 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item role physical scale covers an array of physical health-related role limitations, including: a) limitations in the kind of work or other usual activities; b) reductions in the amount of time spent on work or other usual activities; c) difficulty performing work or other usual activities; and d) accomplishing less. Items in the role physical scale are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role physical domain score represents better role physical functioning.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The bodily pain scale comprises of 2 items pertaining to the intensity of bodily pain and extent of interference with normal work activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher bodily pain domain score represents less bodily pain.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The general health scale consists of 5 items including a rating of health and 4 items addressing the respondent's view and expectations of his or her health. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher general health domain score represents better general health perceptions.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 4-item measure of vitality captures a broad range of subjective evaluations of well-being from feelings of tiredness and being worn out to feeling full of energy all or most of the time. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher vitality domain score represents better vitality.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 2-item social functioning scale assesses health-related effects on quantity and quality of social activities. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher social functioning domain score represents better social functioning.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 3-item role emotional scale assesses mental health-related role limitations in terms of a) time spent in work or other usual activities; b) amount of work or activities accomplished; c) care with which work or other activities were performed. All 3 items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher role emotional domain score represents better role emotional functioning.
Measured: Month 6
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6
The SF-36v2 acute is a 36-item measure that evaluates 8 domains: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The 5-item mental health scale includes 1 or more items from each of 4 major mental health dimensions: anxiety, depression, loss of behavioral/emotional control, and psychological well-being. All items are answered on a 5-point scale. The domain scores were scored using the US 1998 general population norms. The resulting norm-based scores for both the SF-36 v2 and SF-36 health domain scales and component summary measures have means of 50 and standard deviations of 10. A higher mental health domain score represents better mental health functioning.
Measured: Month 6
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6
The WPAI: Rheumatoid Arthritis is a 6 item questionnaire that is specific for rheumatoid arthritis and yields four types of scores: absenteeism, presenteesism (impairment at work/reduced job effectiveness), work productivity loss and activity impairment. WPAI outcomes are expressed as impairment percentages ranging from 0 to 100, with higher numbers indicating greater impairment and less productivity.
Measured: Month 6
Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6
The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). This profile of scores across the 5-dimensions (e.g. 11231, 33212, etc.) is transformed into a single health utility score using a formula developed by the EuroQol Group that applies country specific preference weights. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. The VAS component rated the current health state on a scale ranging from 0 (worst imaginable health state) to 100 (best imaginable health state); higher scores indicating a better health state.
Measured: Month 6
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6
FACIT-F is a 13-item questionnaire. Participants scored each item on a 5-point scale: 0 (not at all) to 4 (very much). The larger the participant's response (with the exception of 2 negatively stated), the greater the participant's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the participant's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score).
Measured: Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2014 (estimated)
- Study startAug 2014
- Primary completionDec 2016
- Study completionDec 2016
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (20)Papers the sponsor has linked to this study.
- Other trials for Rhematoid ArthritisStudies of the same condition, open and under way.
- More trials run by PfizerThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,152 participants (actual)
Sponsor and investigators
- Lead sponsor
- Pfizer
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Pfizer CT.gov Call Center, Study director, Pfizer
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02187055
- Sponsor's protocol ID
- A3921187
- Other IDs
- 2014-000358-13, ORAL STRATEGY, 2014
- Acronym
- ORAL STRATEGY
- Status last verified
- May 2018
- First submitted
- 8 Jul 2014
- Last updated
- 27 Jun 2018
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.
PubMed 42888330Takeuchi T, Tanaka Y, Yamanaka H, Yamaoka K, Sugiyama N, Iikuni N, Toyoizumi S, Kwok K, Tsai WC, Mysler E, Moots RJ, Smolen JS, Fleischmann R. Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis. Rheumatol Ther. 2026 Apr;13(2):423-434. doi: 10.1007/s40744-025-00823-0. Epub 2026 Jan 22.
PubMed 41565911Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
PubMed 39192350Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
PubMed 38958913Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.
PubMed 38883150Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials. Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.
PubMed 37925660Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
PubMed 36931693Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.
PubMed 36814062Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
PubMed 36601090Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
PubMed 36600185Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
PubMed 36526796Bessette L, Mysler E, Kinch CD, Kwok K, Lukic T, On PV, van Vollenhoven RF. Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials. J Rheumatol. 2022 Jun;49(6):566-576. doi: 10.3899/jrheum.210707. Epub 2022 Mar 1.
PubMed 35232809Dikranian A, Gold D, Bessette L, Nash P, Azevedo VF, Wang L, Woolcott J, Shapiro AB, Szumski A, Fleishaker D, Wollenhaupt J. Frequency and Duration of Early Non-serious Adverse Events in Patients with Rheumatoid Arthritis and Psoriatic Arthritis Treated with Tofacitinib. Rheumatol Ther. 2022 Apr;9(2):411-433. doi: 10.1007/s40744-021-00405-w. Epub 2021 Dec 17.
PubMed 34921355Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.
PubMed 34870800Takeuchi T, Fleischmann R, Iikuni N, Shi H, Soma K, Paulissen J, Hirose T, Smolen JS. Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy. Arthritis Res Ther. 2021 Aug 24;23(1):220. doi: 10.1186/s13075-021-02591-y.
PubMed 34429160
Study at a glance
From the registry record, last updated by the sponsor on 27 Jun 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3b/4 Randomized Double Blind Study Of 5 Mg Of Tofacitinib With And Without Methotrexate In Comparison To Adalimumab With Methotrexate In Subjects With Moderately To Severely Active Rheumatoid Arthritis
- ClinicalTrials.gov ID
- NCT02187055
- Acronym / sponsor ID
- ORAL STRATEGY / A3921187
- Conditions
- Rhematoid Arthritis
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,152 participants (actual)
- Lead sponsor
- PfizerIndustry (pharma, biotech, devices)
- Study start
- Aug 2014 (actual)
- Primary completion
- Dec 2016 (actual)
- Study completion
- Dec 2016 (actual)
- First posted
- 10 Jul 2014 (estimated)
- Results
- Posted 27 Jun 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To assess the efficacy of tofacitinib monotherapy or tofacitinib with methotrexate as compared to adalimumab with methotrexate. To compare the efficacy of tofacitinib monotherapy compared to tofacitinib combined with methotrexate. To compare effects on all health outcomes measures in the study. To evaluate the safety and tolerability of tofacitinib and adalimumab. To evaluate the safety of the zoster vaccine given prior to the initiation of tofacitinb or adalimumab.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Tofacitinib 5 mg twice daily with methotrexate | Experimental | Drug: Tofacitinib with methotrexate |
| Tofacitinib 5 mg twice daily monotherapy | Experimental | Drug: Tofacitinib without methotrexate |
| Adalimumab with methotrexate | Active comparator | Biological: Adalimumab with methotrexate |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Have moderate to severe rheumatoid arthritis
- On methotrexate but inadequately controlled
- Subjects must not have active tuberculosis or an inadequately treated tuberculosis infection
- Subjects must use contraception
Key exclusion criteria (4 listed)
- Subjects who have been previously treated with adalimumab or Tofacitinib
- Subjects with any current malignancy or a history of malignancy, with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.
- Subjects with specific laboratory test abnormalities
- Subjects with specific types of infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Tofacitinib with methotrexateTofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months | Drug | Tofacitinib 5 mg twice daily with methotrexate |
| Tofacitinib without methotrexateTofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months | Drug | Tofacitinib 5 mg twice daily monotherapy |
| Adalimumab with methotrexatePlacebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months | Biological | Adalimumab with methotrexate |
Primary outcome
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6
Time frame: Month 6
ACR50 is a greater than or equal to (≥) 50 percent (%) improvement in tender joint count (TJC) or swollen joint count (SJC) and 50% improvement in 3 of the following 5 criteria: 1) physician's global assessment (PGA) of disease activity, 2) participant's assessment (PtGA) of disease activity, 3) participant's assessment of pain, 4) participant's assessment of functional disability via a health assessment questionnaire, and 5) C-reactive protein (CRP) at each visit.
30 secondary outcomes
Change From Baseline in Simplified Disease Activity Index (SDAI) Value at Month 6
Time frame: Month 6
Change From Baseline in Clinical Disease Activity Index (CDAI) Value at Month 6
Time frame: Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including CRP at Month 6
Time frame: Month 6
Change From Baseline in Disease Activity Score 28-4 (DAS28-4) Including Erythrocyte Sedimentation Rate (ESR) at Month 6
Time frame: Month 6
Percentage of Participants Achieving Observed American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean Remission Criteria at Month 6
Time frame: Month 6
Percentage of Participants Achieving SDAI ≤3.3 at Month 6
Time frame: Month 6
Percentage of Participants Achieving CDAI ≤2.8 at Month 6
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (ESR) <2.6 at Month 6
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (CRP) <2.6 at Month 6
Time frame: Month 6
Percentage of Participants Achieving SDAI ≤11 at Month 6
Time frame: Month 6
Percentage of Participants Achieving CDAI ≤10 at Month 6
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (ESR) ≤3.2 at Month 6
Time frame: Month 6
Percentage of Participants Achieving DAS28-4 (CRP) ≤3.2 at Month 6
Time frame: Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 20% Improvement (ACR20) Response at Month 6
Time frame: Month 6
Percentage of Participants Achieving American College of Rheumatology Criteria 70% Improvement (ACR70) Response at Month 6
Time frame: Month 6
Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) at Month 6
Time frame: Month 6
Percentage of Participants Achieving an HAQ-DI Decrease of at Least 0.22 at Month 6
Time frame: Month 6
Change From Baseline in the Short-Form-36 (SF-36) Health Survey, Physical Component Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Mental Component Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Physical Functioning Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Role Physical Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Bodily Pain Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, General Health Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Vitality Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Social Functioning Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Role Emotional Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the SF-36 Health Survey, Mental Health Domain Score at Month 6
Time frame: Month 6
Change From Baseline in the Work Productivity and Activity Impairment (WPAI) Questionnaire at Month 6
Time frame: Month 6
Change From Baseline in the EuroQol European Quality of Life-5 Dimensions (EuroQol EQ-5D) at Month 6
Time frame: Month 6
Change From Baseline in the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale Total Score at Month 6
Time frame: Month 6
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Jun 2018.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 42888330Wright G, Mysler E, Roberts KD, Shelbaya A, Sweet L, Masri KR. Impact of the Sociodemographic Index on Efficacy/Safety of Tofacitinib in Patients with Rheumatoid Arthritis: Post Hoc Analysis of Phase 2/3/3b/4 Studies. Rheumatol Ther. 2026 Oct 16. doi: 10.1007/s40744-026-00881-y. Online ahead of print.
- Derived from this study: PubMed 41565911Takeuchi T, Tanaka Y, Yamanaka H, Yamaoka K, Sugiyama N, Iikuni N, Toyoizumi S, Kwok K, Tsai WC, Mysler E, Moots RJ, Smolen JS, Fleischmann R. Efficacy and Safety of Tofacitinib and Adalimumab in Rheumatoid Arthritis by Body Mass Index-Normalized Methotrexate Dose: A Post Hoc Analysis. Rheumatol Ther. 2026 Apr;13(2):423-434. doi: 10.1007/s40744-025-00823-0. Epub 2026 Jan 22.
- Derived from this study: PubMed 39192350Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.
- Derived from this study: PubMed 38958913Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.
- Derived from this study: PubMed 38883150Pope J, Finckh A, Silva-Fernandez L, Mandl P, Fan H, Rivas JL, Valderrama M, Montoro M. Tofacitinib Monotherapy in Rheumatoid Arthritis: Clinical Trials and Real-World Data Contextualization of Patients, Efficacy, and Treatment Retention. Open Access Rheumatol. 2024 Jun 11;16:115-126. doi: 10.2147/OARRR.S446431. eCollection 2024.
- Derived from this study: PubMed 37925660Citera G, Jain R, Irazoque F, Madariaga H, Gruben D, Wang L, Stockert L, Santana K, Ebrahim A, Ponce de Leon D. Tofacitinib Efficacy in Patients with Rheumatoid Arthritis and Probable Depression/Anxiety: Post Hoc Analysis of Phase 3 and 3b/4 Randomized Controlled Trials. Rheumatol Ther. 2024 Feb;11(1):35-50. doi: 10.1007/s40744-023-00612-7. Epub 2023 Nov 5.
- Derived from this study: PubMed 36931693Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.
- Derived from this study: PubMed 36814062Dougados M, Taylor PC, Bingham CO 3rd, Fallon L, Brault Y, Roychoudhury S, Wang L, Kessouri M. The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis. RMD Open. 2022 Sep;8(2):e002478. doi: 10.1136/rmdopen-2022-002478.
- Derived from this study: PubMed 36601090Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.
- Derived from this study: PubMed 36600185Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.
- Derived from this study: PubMed 36526796Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.
- Derived from this study: PubMed 35232809Bessette L, Mysler E, Kinch CD, Kwok K, Lukic T, On PV, van Vollenhoven RF. Impact of Tofacitinib on Components of the ACR Response Criteria: Post Hoc Analysis of Phase III and Phase IIIb/IV Trials. J Rheumatol. 2022 Jun;49(6):566-576. doi: 10.3899/jrheum.210707. Epub 2022 Mar 1.
- To obtain contact information for a study center near you, click here.Link provided by the sponsor.
Related trials for Rhematoid Arthritis
RecruitingObservational study
Tornier Perform™ Reversed Monopost Study
Non-inflammatory Degenerative Joint Disease, Rhematoid Arthritis
RecruitingPhase 1
A Phase 1 Study of JADE201 in Participants With Rheumatoid Arthritis
Rhematoid Arthritis
Enrolling by invitationObservational study
Persona SoluTion PPS Femur PMCF
Rhematoid Arthritis, Osteo Arthritis of the Knee
Not yet recruiting
Wrist Nerve Block as a New Treatment in Patients With Rheumatoid Arthritis
Rhematoid Arthritis
Not yet recruitingObservational study
Kinesiophobia in Rheumatoid Arthritis: Associations With Functional Disability, Disease Activity, and Related Clinical Factors
Kinesiophobia (Fear of Movement), Rhematoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pfizer CT.gov Call Center study director
Pfizer
215 sites in 25 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Tofacitinib with methotrexate, Tofacitinib without methotrexate and Adalimumab with methotrexate in people with Rhematoid Arthritis, run by Pfizer at 215 sites in 25 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Jun 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 215 sites in United States, Poland, Russia, Mexico, South Africa and 20 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 27 Jun 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants Achieving American College of Rheumatology Criteria 50% Improvement (ACR50) Response at Month 6 (time frame: Month 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02187055, which also lists 20 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Jun 2018.